{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:48:04Z","timestamp":1781725684262,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972898"],"award-info":[{"award-number":["81972898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272837"],"award-info":[{"award-number":["82272837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172713"],"award-info":[{"award-number":["82172713"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1515020008"],"award-info":[{"award-number":["2023B1515020008"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["22ykqb15"],"award-info":[{"award-number":["22ykqb15"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114203","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:03:58Z","timestamp":1720213438000},"page":"114203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials"],"prefix":"10.1016","volume":"208","author":[{"given":"Yixin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.114203_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ejca.2024.114203_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.114203_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114203_bib4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.ejca.2024.114203_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosom Med"},{"issue":"13","key":"10.1016\/j.ejca.2024.114203_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(11)70268-6","article-title":"Nocebo side-effects in cancer treatment","volume":"12","author":"Garg","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114203_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5617","article-title":"Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the adjuvant setting: a systematic review and meta-analysis","volume":"1","author":"Chac\u00f3n","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.ejca.2024.114203_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.amjmed.2022.06.007","article-title":"Nocebo vs placebo effects: their clinical relevance","volume":"135","author":"Tavel","year":"2022","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.114203_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastas-- Rev"},{"issue":"12","key":"10.1016\/j.ejca.2024.114203_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114203_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2024.114203_bib12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.ejca.2024.114203_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"issue":"10","key":"10.1016\/j.ejca.2024.114203_bib14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2215-0366(19)30289-5","article-title":"Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis","volume":"6","author":"Lai","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.ejca.2024.114203_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"issue":"16","key":"10.1016\/j.ejca.2024.114203_bib16","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1002\/sim.8158","article-title":"Network meta-analysis of rare events using the Mantel-Haenszel method","volume":"38","author":"Efthimiou","year":"2019","journal-title":"Stat Med"},{"issue":"7414","key":"10.1016\/j.ejca.2024.114203_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.ejca.2024.114203_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.ejca.2024.114203_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pain.2009.07.010","article-title":"A systematic review of adverse events in placebo groups of anti-migraine clinical trials","volume":"146","author":"Amanzio","year":"2009","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.ejca.2024.114203_bib20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejca.2024.114203_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101685","article-title":"The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis","volume":"54","author":"Chin","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.ejca.2024.114203_bib22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejca.2024.114203_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/ehjqcco\/qcac060","article-title":"Meta-analysis of the placebo and nocebo effects associated with placebo treatment in randomized trials of lipid-lowering therapies","volume":"9","author":"Chin","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"9","key":"10.1016\/j.ejca.2024.114203_bib24","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.21873\/anticanres.15266","article-title":"Anemia in placebo arms of cancer studies","volume":"41","author":"Wolff","year":"2021","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.114203_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21873\/anticanres.15455","article-title":"Fatigue in cancer treatment studies: analysis of placebo arms","volume":"42","author":"Hauch","year":"2022","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2024.114203_bib26","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.21873\/anticanres.15761","article-title":"Adverse events in placebo arms of cancer trials","volume":"42","author":"Wolff","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2024.114203_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2022.04.022","article-title":"Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: a systematic review and meta-analysis","volume":"170","author":"Simon","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114203_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.114203_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, Version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"10.1016\/j.ejca.2024.114203_bib30","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114203_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1744666X.2018.1516144","article-title":"The role of placebo effects in immune-related conditions: mechanisms and clinical considerations","volume":"14","author":"Smits","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114203_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and nocebo effects","volume":"382","author":"Colloca","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114203_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41380-021-01365-x","article-title":"Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission","volume":"27","author":"Prossin","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ejca.2024.114203_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.irn.2018.01.001","article-title":"Placebo effects in the immune system","volume":"138","author":"Hadamitzky","year":"2018","journal-title":"Int Rev Neurobiol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114203_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1530\/EJE-15-1119","article-title":"The placebo effect in thyroid cancer: a meta-analysis","volume":"174","author":"Llavero-Valero","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114203_bib36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114203_bib37","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.ejca.2024.114203_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.114203_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114203_bib40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/djp132","article-title":"Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon","volume":"101","author":"Bouwhuis","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.ejca.2024.114203_bib41","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2009.24.6264","article-title":"Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991","volume":"28","author":"Bouwhuis","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:59Z","timestamp":1762342559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"alternative-id":["S0959804924008591"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114203","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114203"}}